Published on: 22.06.2020, 1 h and 20 min.
In this discussion, round experts from Switzerland and Germany discuss practice-changing studies with the ASCO2020 original authors.
The following authors are presenting their studies:
Dr. Fatima Cardoso
Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients
Dr. Javier Cortes
Breast Cancer Program, IOB Institute of Oncology, Madrid & Barcelona, Spain
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Prof. Dr. Andreas du Bois
Department Gynecology & Gyn.Oncology KEM, Evang. Kliniken Essen-Mitte gGmbH, Essen, Germany
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.
ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.